NeuraSignal Platform
The NeuraSignal Platform provides a real-time assessment of cerebral hemodynamics, making it a valuable tool in the diagnosis and treatment of cerebrovascular disease.
Our Products
NG2 Intelligent Ultrasound
NG2 Classic Ultrasound
NG View
NeuraCare
Discover the power of the NeuraSignal Platform
NeuraSignal is committed to providing the support and guidance needed to ensure success.
Revolutionizing TCD Ultrasound for Every Practitioner
The NeuraSignal Platform was designed to make complex cerebral exams easy to perform. Automated signal acquisition and advanced exam analysis reduces the need for specialized TCD expertise, allowing for use by a wider range of healthcare providers and hospitals.
- Accurate and reliable neurological assessments.
- Improved clinical outcomes and patient care.
- Streamlined workflow for all levels of expertise.
What's New
Donation will provide Ukrainian physicians with hands-on transcranial Doppler training and expand access to neurovascular technology amid ongoing healthcare challenges LOS ANGELES, Calif. — September 1, …
LOS ANGELES, CA July 22, 2026 — NeuraSignal Inc., a neurovascular technology company advancing robotic transcranial Doppler ultrasound, is showcasing Royal Columbian Hospital's use of …
A 37-year-old father was warming up his car while his wife buckled their daughter into her car seat. Then suddenly, his fingers started going numb …
For clinic directors and healthcare decision-makers evaluating diagnostic capabilities, cerebrovascular reserve (CVR) testing represents one of the most clinically impactful—and underutilized—tools in modern neurology. The …
Hospitals that invest in transcranial Doppler ultrasound don't just need technology that works. They need a program that works, one where clinicians feel confident, workflows …
Cardiac arrest remains one of the most devastating medical emergencies worldwide. While advances in resuscitation science have improved rates of return of spontaneous circulation (ROSC), …
TCD Applications
The NeuraSignal Platform provides rapid, noninvasive, real-time measures of cerebrovascular function. Physicians and accreditation commissions recommend TCD as a highly accurate and sensitive test for patients with stroke or stroke-like symptoms. It is used to diagnose a wide range of conditions affecting blood flow to, and within, the brain.
In a recent study with non-expert TCD operators, the NeuraSignal Platform exhibited a >3X detection rate for a right-to-left shunt (RLS) and a 2.7X detection rate for patients with large, intervenable shunts as compared to standard of care transthoracic echocardiography (TTE).3 Without appropriate diagnosis and intervention, many of these patients are at a high risk of stroke recurrence. Furthermore, the autonomous, robotic headset makes it easy for a bubble study to be completed by one person, helping to alleviate personnel shortages.
After a subarachnoid hemorrhage (SAH), guidelines state that patients should receive daily TCD monitoring. Thanks to its ease of use, NG 2 enables TCD exams to be performed any time of the day or night, giving clinicians the ability to immediately monitor a patient if their condition is deteriorating. The exam does not subject patients to harmful radiation and can reduce the number of CT-As performed. A prospective study demonstrated that the use of TCD combined with clinical management of post-SAH patients could reduce ICU stays by an average of 8 days, or $24,000 per patient.4
TCD is the only diagnostic modality able to assess blood flow in the brain in real time.5 By using the NeuraSignal Platform to monitor changes in cerebral hemodynamics during a procedure, clinicians can identify potential complications and take appropriate action to prevent ischemia or other adverse outcomes while the patient is still in the OR. TCD is currently the gold-standard test to detect, localize, and quantify cerebral embolism. It has been used in aortic surgery to confirm cerebral perfusion and during cardiopulmonary bypass surgery to monitor microemboli.
After mechanical thrombectomy, it is crucial to monitor blood flow in the brain to quickly detect any complications that may arise. The NeuraSignal Platform provides continuous monitoring of cerebral hemodynamics, helping clinicians to quickly and easily identify changes indicative of complications like reocclusion or hemorrhage. TCD has been successfully used to guide post-thrombectomy blood pressure management for the prevention of complication and injury.6
Book a Live Demo
Let's Get started
By providing noninvasive monitoring of cerebral hemodynamics, the NeuraSignal Platform can reduce the need for more invasive and costly procedures, delivering cost savings and increasing efficiency.
With real-time information, clinical teams can make more informed decisions about patient management, leading to reduced length of stay and improving patient outcomes.
With the NeuraSignal Platform, healthcare professionals can detect and manage complications more quickly, helping to prevent adverse outcomes, reduce hospital readmissions, and ultimately leading to better patient satisfaction.